A new study published by MD Anderson Cancer Center researchers in Cell Stem Cell describes a technique that can separate prostate cancer cells based on their levels of prostate-specific antigen, says an MD Anderson press release. Further, the team says its ability to separate low-PSA and high-PSA cells led to the discovery of a low-PSA population of cancer stem cells that seem to be important in the development of castration-resistant prostate cancer. "In cell lines and mouse model experiments, the low-PSA cells resisted chemotherapy and thrived under hormone deprivation," the release adds. "Low-PSA cells were found to be both self-renewing and capable of differentiating into other prostate cancer cell types upon division." These findings may help researchers develop new therapeutics specifically targeted to low-PSA cells.
A Difficult Cancer Elucidated
May 05, 2012